The production of epolones A and B has only been reported once during investigations by OSI Pharmaceuticals for an alternative drug treatment to the use of recombinant human erythropoietin for anemia caused by chronic renal failure, cancer chemotherapy, and a variety of other disease states (Cai et al. 1998). The gene discussed is EPO; the disease is chronic kidney disease.